Citigroup Inc. has recently filed a pricing supplement for its new medium-term senior notes, which are linked to the EURO STOXX 50 Index. This strategic move reflects Citigroup's ongoing efforts to diversify its financial products and enhance its market offerings.
The filing, dated November 12, 2026, outlines the details of the securities, which are classified as unsecured debt securities issued by Citigroup Global Markets Holdings Inc. and guaranteed by Citigroup Inc. Unlike traditional debt securities, these notes do not pay interest and do not guarantee the repayment of principal at maturity, introducing a unique risk profile for investors.
Background
Citigroup Inc. is a prominent player in the financial services industry, classified under the SIC code 6021, which pertains to National Commercial Banks. The company operates on the New York Stock Exchange under the ticker symbols C, C-PN, and C-PR. Citigroup has a long history of providing various financial services, including investment banking, consumer banking, and wealth management.
What the Filing Says
The filing states that the securities offer potential for automatic early redemption at a premium based on the performance of the underlying index. If the closing value of the EURO STOXX 50 Index is greater than or equal to the initial value on specified valuation dates, the securities may be redeemed early. However, if the index performs poorly, investors may face significant losses.
Impact
This development may affect a broad range of investors, particularly those seeking exposure to equity-linked securities. Given the unique structure of these notes, they may attract investors looking for potential high returns, albeit with increased risk. The filing indicates that all payments are subject to the credit risk of both Citigroup Global Markets Holdings Inc. and Citigroup Inc.
What's Next
The filing does not specify what happens next regarding the issuance of these securities. However, investors can expect further communications from Citigroup as they finalize the offering and provide additional details on the performance of the notes.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










